BioCentury | Feb 10, 2020
Finance

Woodford pain continues as report suggests deal to sell private biotech stakes falls through

Private biotech companies held by funds formerly managed by Neil Woodford haven’t rid themselves of the debacle that led to the star British investor’s demise. According to a report in The Times that did not...
BioCentury | Oct 19, 2019
Finance

Woodford’s empire crumbles. U.K biotech stays standing

Perhaps the greatest sign of robustness of the U.K. biotech sector is that it barely budged on the news this week of Neil Woodford’s demise. Woodford’s struggles came to an acrimonious and swift end as...
BC Week In Review | Aug 10, 2015
Clinical News

OXPzero Naproxen: Phase I data

An open-label, U.K. Phase I trial in patients with upper gastrointestinal tract irritation showed that 250 mg OXP005 missed the co-primary endpoints of reducing the severity of gastroduodenal irritation in the stomach and duodenum as...
BC Week In Review | Jun 8, 2015
Financial News

Oxford Pharmascience Group proposes placing

Oxford Pharmascience Group plc (LSE:OXP), Yarnton, U.K.   Business: Drug delivery, Neurology, Cardiovascular   Date announced: 2015-06-02   Type: Placing   To be raised: Up to L20 million ($30.5 million)   Shares: 200 million  ...
BC Week In Review | Nov 3, 2014
Company News

Sigmoid Pharma, Pharmascience deal

Sigmoid granted Pharmascience's Pendopharm division exclusive rights to commercialize CyCol in Canada. Pendopharm invested EUR5 million ($6.4 million) in Sigmoid, which will also receive an undisclosed upfront payment and is eligible for milestones and double-digit...
BC Week In Review | Aug 18, 2014
Clinical News

Single-agent ribavirin regulatory update

Pharmascience’s Pendopharm division said Health Canada approved single-agent Ibavyr ribavirin to treat HCV infection. Pendopharm said that ribavirin is available only in kits with interferon in Canada and that its product would be the first,...
BC Innovations | Jul 17, 2014
Targets & Mechanisms

Hedgehog joins the resistance

Increased glucuronidation by activated hedgehog signaling turns out to be the root of drug resistance for at least two compounds in acute myeloid leukemia. 1 Inhibiting the pathway could avoid the toxicity of general glucuronidase...
BC Week In Review | Jun 23, 2014
Clinical News

OXP001: Phase I data

A single-blind, U.K. Phase I trial in 43 healthy volunteers showed that OXP001 met the primary endpoint of reducing gastric irritation as measured by mean Lanza score vs. Brufen ibuprofen (reduction of 0.9 compared to...
BC Week In Review | Apr 7, 2014
Clinical News

Single-agent ribavirin regulatory update

Pharmascience's Pendopharm division said Health Canada granted Priority Review to an application for single-agent ribavirin to treat HCV infection. Pendopharm said that ribavirin is available only in kits with interferon in Canada and that its...
BC Week In Review | Mar 24, 2014
Company News

Oxford Pharmascience Group management update

Oxford Pharmascience Group plc (LSE:OXP), Yamton, U.K.   Business: Nutraceuticals, Drug delivery   Hired: Liz King as director of R&D, formerly associate director of operations at Pharmalink Consulting  ...
Items per page:
1 - 10 of 43
BioCentury | Feb 10, 2020
Finance

Woodford pain continues as report suggests deal to sell private biotech stakes falls through

Private biotech companies held by funds formerly managed by Neil Woodford haven’t rid themselves of the debacle that led to the star British investor’s demise. According to a report in The Times that did not...
BioCentury | Oct 19, 2019
Finance

Woodford’s empire crumbles. U.K biotech stays standing

Perhaps the greatest sign of robustness of the U.K. biotech sector is that it barely budged on the news this week of Neil Woodford’s demise. Woodford’s struggles came to an acrimonious and swift end as...
BC Week In Review | Aug 10, 2015
Clinical News

OXPzero Naproxen: Phase I data

An open-label, U.K. Phase I trial in patients with upper gastrointestinal tract irritation showed that 250 mg OXP005 missed the co-primary endpoints of reducing the severity of gastroduodenal irritation in the stomach and duodenum as...
BC Week In Review | Jun 8, 2015
Financial News

Oxford Pharmascience Group proposes placing

Oxford Pharmascience Group plc (LSE:OXP), Yarnton, U.K.   Business: Drug delivery, Neurology, Cardiovascular   Date announced: 2015-06-02   Type: Placing   To be raised: Up to L20 million ($30.5 million)   Shares: 200 million  ...
BC Week In Review | Nov 3, 2014
Company News

Sigmoid Pharma, Pharmascience deal

Sigmoid granted Pharmascience's Pendopharm division exclusive rights to commercialize CyCol in Canada. Pendopharm invested EUR5 million ($6.4 million) in Sigmoid, which will also receive an undisclosed upfront payment and is eligible for milestones and double-digit...
BC Week In Review | Aug 18, 2014
Clinical News

Single-agent ribavirin regulatory update

Pharmascience’s Pendopharm division said Health Canada approved single-agent Ibavyr ribavirin to treat HCV infection. Pendopharm said that ribavirin is available only in kits with interferon in Canada and that its product would be the first,...
BC Innovations | Jul 17, 2014
Targets & Mechanisms

Hedgehog joins the resistance

Increased glucuronidation by activated hedgehog signaling turns out to be the root of drug resistance for at least two compounds in acute myeloid leukemia. 1 Inhibiting the pathway could avoid the toxicity of general glucuronidase...
BC Week In Review | Jun 23, 2014
Clinical News

OXP001: Phase I data

A single-blind, U.K. Phase I trial in 43 healthy volunteers showed that OXP001 met the primary endpoint of reducing gastric irritation as measured by mean Lanza score vs. Brufen ibuprofen (reduction of 0.9 compared to...
BC Week In Review | Apr 7, 2014
Clinical News

Single-agent ribavirin regulatory update

Pharmascience's Pendopharm division said Health Canada granted Priority Review to an application for single-agent ribavirin to treat HCV infection. Pendopharm said that ribavirin is available only in kits with interferon in Canada and that its...
BC Week In Review | Mar 24, 2014
Company News

Oxford Pharmascience Group management update

Oxford Pharmascience Group plc (LSE:OXP), Yamton, U.K.   Business: Nutraceuticals, Drug delivery   Hired: Liz King as director of R&D, formerly associate director of operations at Pharmalink Consulting  ...
Items per page:
1 - 10 of 43